JP2013047274A - Neisseria配合組成物 - Google Patents
Neisseria配合組成物 Download PDFInfo
- Publication number
- JP2013047274A JP2013047274A JP2012256105A JP2012256105A JP2013047274A JP 2013047274 A JP2013047274 A JP 2013047274A JP 2012256105 A JP2012256105 A JP 2012256105A JP 2012256105 A JP2012256105 A JP 2012256105A JP 2013047274 A JP2013047274 A JP 2013047274A
- Authority
- JP
- Japan
- Prior art keywords
- strains
- nspa
- neisseria
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 63
- 241000588653 Neisseria Species 0.000 title abstract description 37
- 241000588650 Neisseria meningitidis Species 0.000 abstract description 20
- 229960005486 vaccine Drugs 0.000 abstract description 10
- 241000588652 Neisseria gonorrhoeae Species 0.000 abstract description 7
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 abstract description 2
- 206010027249 Meningitis meningococcal Diseases 0.000 abstract 1
- 201000010924 Meningococcal meningitis Diseases 0.000 abstract 1
- 229960005037 meningococcal vaccines Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 75
- 102000004169 proteins and genes Human genes 0.000 description 72
- 235000018102 proteins Nutrition 0.000 description 71
- 230000000890 antigenic effect Effects 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 150000004676 glycans Chemical class 0.000 description 18
- 229920001282 polysaccharide Polymers 0.000 description 18
- 239000005017 polysaccharide Substances 0.000 description 18
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100040307 Protein FAM3B Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101710087110 ORF6 protein Proteins 0.000 description 4
- 101710197985 Probable protein Rev Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 101150095079 menB gene Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102000017033 Porins Human genes 0.000 description 3
- 108010013381 Porins Proteins 0.000 description 3
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 101150075249 ORF40 gene Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 101100156835 Paenarthrobacter nicotinovorans xdh gene Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000037941 meningococcal disease Diseases 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- -1 pH 5.8 Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 101100059051 Acidianus filamentous virus 1 (isolate United States/Yellowstone) ORF132 gene Proteins 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- 101000748781 Anthoceros angustus Uncharacterized 3.0 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 1
- 101000616308 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg00120 Proteins 0.000 description 1
- 101100214860 Autographa californica nuclear polyhedrosis virus Ac132 gene Proteins 0.000 description 1
- 101100074342 Autographa californica nuclear polyhedrosis virus LEF-11 gene Proteins 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000847476 Autographa californica nuclear polyhedrosis virus Uncharacterized 54.7 kDa protein in IAP1-SOD intergenic region Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000736075 Bacillus subtilis (strain 168) Uncharacterized protein YcbP Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000916131 Bacillus subtilis (strain 168) Uncharacterized protein YqxA Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 0 CC(CC1)*1N(C)* Chemical compound CC(CC1)*1N(C)* 0.000 description 1
- TXNJAVCZNMSELK-UHFFFAOYSA-N CCCCCCCCCCCCOC(=O)CNC Chemical compound CCCCCCCCCCCCOC(=O)CNC TXNJAVCZNMSELK-UHFFFAOYSA-N 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101000748765 Chlorella vulgaris Uncharacterized 16.5 kDa protein in psaC-atpA intergenic region Proteins 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 101000792449 Cyanophora paradoxa Uncharacterized 3.4 kDa protein in atpE-petA intergenic region Proteins 0.000 description 1
- 102100024101 DnaJ homolog subfamily C member 28 Human genes 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 101000792455 Euglena longa Uncharacterized 13.3 kDa protein in rpl23-rpl2 intergenic region Proteins 0.000 description 1
- 101000748747 Euglena longa Uncharacterized 9.2 kDa protein in rpl23-rpl2 intergenic region Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- 101000626971 Guillardia theta Uncharacterized 8.1 kDa protein Proteins 0.000 description 1
- 101001066788 Haemophilus phage HP1 (strain HP1c1) Probable portal protein Proteins 0.000 description 1
- 101000758963 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 12.7 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000976893 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.1 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101000708358 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 23.3 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000786921 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 26.0 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000748192 Herpetosiphon aurantiacus Uncharacterized 15.4 kDa protein in HgiDIIM 5'region Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000941045 Homo sapiens Cortactin-binding protein 2 Proteins 0.000 description 1
- 101001053999 Homo sapiens DnaJ homolog subfamily C member 28 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 101000626970 Marchantia polymorpha Uncharacterized 3.3 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 1
- 101000788536 Marchantia polymorpha Uncharacterized mitochondrial protein ymf22 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150083029 ORF147 gene Proteins 0.000 description 1
- 101150020791 ORF37 gene Proteins 0.000 description 1
- 101100028042 Orgyia pseudotsugata multicapsid polyhedrosis virus OPEP-3 gene Proteins 0.000 description 1
- 101100083931 Orgyia pseudotsugata multicapsid polyhedrosis virus P26 gene Proteins 0.000 description 1
- 101000783504 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 15.4 kDa protein Proteins 0.000 description 1
- 101000770899 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.3 kDa protein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000768120 Oryza nivara Uncharacterized protein ycf76 Proteins 0.000 description 1
- 101710137396 Protein ORF1 Proteins 0.000 description 1
- 101710132845 Protein P1 Proteins 0.000 description 1
- 241000745900 Psychrobacter meningitidis Species 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 101000788145 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Uncharacterized protein YpfL Proteins 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
- 101000764204 Trieres chinensis Uncharacterized 3.3 kDa protein in rpl11-trnW intergenic region Proteins 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 101710172656 Uncharacterized protein ycf70 Proteins 0.000 description 1
- 101710172664 Uncharacterized protein ycf72 Proteins 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- IHYWGCXYIMQWQF-UHFFFAOYSA-N costatin Natural products OC1=C(O)C(CC=C(C)C)=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C(CC=C(C)C)=C3OC2=C1 IHYWGCXYIMQWQF-UHFFFAOYSA-N 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 101150055782 gH gene Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940071204 lauryl sarcosinate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
【解決手段】Neisseria(ナイセリア)細菌、特にN.meningitidisおよびN.gonorrhoeae由来の生物学的分子の組合せを含む組成物。
【選択図】なし
Description
本発明は、Neisseria(ナイセリア)細菌、特にN.meningitidisおよびN.gonorrhoeae由来の生物学的分子の組合せを含む組成物に関する。
Neisseria meningitidisおよびNeisseria gonorrhoeaeは、非運動性であり、ヒトにおいて病原性であるグラム陰性の双球菌である。
(項目1) Neisseria細菌由来の第一の生物学的分子およびNeisseria細菌由来の第二の生物学的分子を含む、組成物。
(項目2) 上記第一の生物学的分子が配列番号1〜8376からなる群より選択される、項目1に記載の組成物。
(項目3) 上記第一の生物学的分子が配列番号1〜4002からなる群より選択される、項目2に記載の組成物。
(項目4) 上記第二の生物学的分子が配列番号1〜8376からなる群より選択される、項目1〜3のいずれかに記載の組成物。
(項目5) 上記第二の生物学的分子が配列番号1〜4002からなる群より選択される、項目4に記載の組成物。
(項目6) 配列番号1〜4002より選択される2以上の生物学的分子を含む、項目1〜4のいずれか1つに記載の組成物。
(項目7) 配列番号4003〜8376より選択される1以上の生物学的分子と組合せられる、配列番号1〜4002より選択される1以上の生物学的分子を含む、項目1〜4のいずれか1つに記載の組成物。
(項目8) 好ましくは成熟形態のWO96/29412に開示されるNspAタンパク質と組合せられる、配列番号1〜4002および4057〜83
76より選択される1以上の生物学的分子を含む、項目1〜4のいずれか1つに記載の組成物。
(項目9) 953タンパク質と組合せられる、配列番号1〜8376より選択される1以上の生物学的分子を含む、項目1〜4のいずれか1つに記載の組成物。
(項目10) 医薬としての使用のための、項目1〜9のいずれかに記載の組成物。
Neisseriaタンパク質およびヌクレオチドの配列は、以下の文書に開示される:
・WO99/24578
・WO99/36544
・WO99/57280
・WO97/28273
・WO96/29412
・WO95/03413
・Tettelinら(2000)Science 287:1809−1815。
したがって、本発明は、配列番号1〜8376の35074500個の可能な対の各々(1および2、1および3、1および4、1および5、・・・ 1および8375、1および8376、2および3、2および4、2および5、… 2および8375、2および8376、3および4、・・・ 1000および1001、1000および1002、・・・ 1000および8376、・・・ 8374および8375、8374および8376、8375および8376)を包含するが、スペースの都合で、その全てをここに列挙していない。
・配列番号1〜4002から選択される2つ以上の生物学的分子;
・配列番号1〜4002から選択される1つ以上の生物学的分子と配列番号4003〜8376から選択される1つ以上の生物学的分子の組み合わせ;
・配列番号1〜4002から選択される1つ以上の生物学的分子とNspAタンパク質(WO96/29412に開示されるもの;本願明細書の図29もまた参照のこと)(好ましくは、成熟形態)との組み合わせ;
・配列番号1〜8376(好ましくは、配列番号1〜4002)から選択される1つ以上の生物学的分子とトランスフェリン結合タンパク質A(TbpA)および/またはB(TbpB)(例えば、WO00/25811に開示されるTbpAおよびTbpB(またはそれらの免疫原性フラグメント))との組み合わせ;
・配列番号1〜4002から選択されるタンパク質の1つ以上のフラグメントと好ましくは、保存されたアミノ酸のストレッチを含むフラグメントとの組み合わせ;
・異なるタンパク質の組み合わせであって、ここで、その組み合わせは、全体として、参照集団において各菌株によって認識される1つ以上のタンパク質を含むが、その組み合わせ中の各個々のタンパク質は、それ自体、参照集団において各菌株によって認識されないかもしれない、すなわち、参照集団の各メンバーは、少なくとも1つのタンパク質をその組み合わせにおいて認識する。
(実施例1−発現および精製実験)
WO99/24578に開示された、ORF6、7、13、65−1、72、73−1、105−1、137−1、143−1および147−1を、以下の表に示されるように、E.coli中で発現させ、そして精製した。
WO99/24578に開示されたORF9を、pETベクター中にクローン化し、そしてE.coliにおいて発現させた。精製されたORF−His融合タンパク質を、図2Aに示されるように、SDS−PAGEによって分析した。精製されたORF9−Hisを用いて、マウスに免疫し、そしてウェスタンブロット分析(図2B)、FACS分析(図2C)、およびELISAアッセイのために血清を使用した。使用されたプロトコールは、WO99/24578に示されたプロトコールと本質的に同じである。
さらなる発現および精製実験を、以下の表に示されるように、WO99/24578に開示されたORF2−1、5−1、22−1、および132−1について、E.coli中で実施した。
これらの4つのORFを発現させるために使用されたプロトコールは、本質的にWO99/24578に記載されたプロトコールと同じであり、pGEXおよびpETベクターを使用した。ORFを増幅するために使用したPCRプライマーの例は、以下の表の通りである。
ORF4は、リポペプチドシグナル配列(LPSS)を含むとして、WO99/24578に開示されている。全長ORFを、以下のPCRプライマーを使用して増幅した。
orf4−L(順方向)
CGCGGATCCCATATGAAAACCTTCTTCAAAACCorf4−L(順方向)
CCCGCTCGAGTTATTTGGCTGCGCCTTC。
ORF2、5、6a、7、9、13a、15、22、23、27、28、32、65、72、73、76、79、89、105、106−1、132、137、138、143、および147(WO99/24578において開示される)のコンピューター分析を実施した。図4〜28は、これらの各ORFに関する、親水性プロット(上段)、抗原性指数プロット(中段)、およびAMPHI分析(下段)を示す。AMPHIプログラムを使用して、T細胞エピトープを推定した[Gaoら(1989)、J.Immunol.143:3007;Robertsら(1996)AIDS Res Hum Retrovir 12:593;Quakyiら(1992)Scand J Immunol、補遺11:9]。AMPHIプログラムは、DNASTAR,Inc.(1228 South Park Street、Madison、Wisconsin 53715 USA)のProteanソフトウェアパッケージで利用可能である。
タンパク質919(WO99/57280)、225(WO99/57280)、ORF4(WO99/24578、実施例26)、およびORF40(WO99/36544、実施例1)の混合物を生成し、そしてELISAおよびFACSによってアッセイした。13試験菌株に対するELISA力価は、以下の通りであった。
FACSの結果を、図33に示す。この四価混合物が、使用された特定のmemB菌株とは無関係に、優れた結果を与えることは明らかである。さらに、菌株2996中で、この混合物に対して惹起された抗血清は、希釈率1:2048まで殺菌性である。
タンパク質ORF4−L(脂質化タンパク質、上記実施例4を参照のこと)、ORF37(WO99/24578、実施例1)、ORF40(WO99/36544、実施例1)、502(WO99/57280、687〜690頁)、および8(WO99/57280、165〜167頁)の混合物を生成した。13試験菌株に対するELISA力価は、以下の通りであった。
FACSの結果を、図34に示す。この五価混合物が、使用された特定のmemB菌株とは無関係に、優れた結果を与えることは明らかである。さらに、菌株2996中で、この混合物に対して惹起された抗血清は、静菌性である。
タンパク質ORF1(例えば、WO99/24578の実施例77;WO99/55873もまたを参照のこと)、「287」(例えば、WO99/57280の図21;その中の配列番号3103〜3108もまたを参照のこと)、および「919」(例えば、WO99/57280の図23およびその中の配列番号3069〜3074)を組合せ、そしてAl(OH)3でアジュバント処理(adjuvant)した。このタンパク質は、
MemBの菌株2996由来である。
(実施例9−タンパク質287、919、および953)
タンパク質287、919、および953は、WO99/57280に開示される。N.meningitidis血清型Bの菌株2996由来のこれらのタンパク質を発現させ、そして単独または組合せにおいて、菌株2996に対する殺菌アッセイにおいて試験した。2996由来のOMVを、陽性コントロールとして使用した。
本実施例において使用された3つのタンパク質を、以下の形態で発現させ、そして使用した:
(1)タンパク質287を、GST融合物としてE.coli中で発現させた;
(2)タンパク質919を、そのリーダーペプチドを伴なわず、その成熟N末端システインを伴なわず、そしていかなる融合パートナー(「919−untag」)をも伴なわずに、E.coli中で発現させた;および
(3)タンパク質953を、ヒスチジンタグを使用して発現させた。
さらなる抗原の組合せを、CD1マウスにおいて試験した。
*:「his」は、ヒスチジンタグ化タンパク質での発現および免疫を示す;
「ORF4−L」は、ORF4の脂質化形態である;
「GST」は、GST融合タンパク質での発現および免疫を示す;
「919−untag」は、実施例9に規定される通りである;
「MenC glycoconj」は、実施例8に記載される、MenC複合糖質である。
NspAタンパク質は、WO96/29412において開示され、そして本明細書中に配列番号4008〜4033として表される。このタンパク質の学術文献の開示[Martinら(1997)J.Exp.Med.185 1173−1183]は、このタンパク質が、Neisseria菌株間で高度に保存されること(250の髄膜炎菌A、B、およびC菌株と抗NspA抗体との交差反応性は99%である)、そしてまた生細菌での致死的なチャレンジに対する効率的な防御を報告した。ミョウバン上に吸着されたNspAは、ウサギおよびサルにおいて血清髄膜炎殺菌抗体応答を惹起するとの報告もある[Martinら(1998)Abstract of 11th International pathogenic Neisseria conference.page
198]。これらのデータに基づいて、rNspA(組換えNspA)は、全血清群により引き起こされる髄膜炎菌疾患の予防のためのワクチンとして開発されつつある。
た。細菌を5000gで15分間の遠心分離によって採集し、0.6mlの10mM Hepes、pH8.0中で洗浄し、次いで10mM EDTAを含む0.6mlの同じ緩衝液中で再懸濁し、そして37℃で1時間インキュベートした。細胞を10,000gで1分間ペレット化し、そして上清中に放出された髄膜炎菌B多糖抗原の相対量を、Azmiら[Infect.Immun.(1995)63:1906−13]により記載のように行ったインヒビションELISAによって決定した。ELISA中の固相抗原は、アビジンコーティングマイクロタイタープレートに吸着された髄膜炎菌B多糖−ADH−ビオチン[Granoffら]であった。髄膜炎菌B多糖反応性ヒトパラプロチンLIP[Azmiら]を、一次抗体として使用した(0.2μg/ml)。インヒビターの非存在下で、この抗体濃度は、基質と30分インキュベートした後に約0.7〜1.0のODを与えるのに十分であった[Azmiら]。上清に放出された多糖の力価を、抗体結合50%阻害を生じた上清の希釈を決定することにより測定した。本アッセイ中のコントロールは、菌株M7(これはいかなる被嚢多糖も生成しない)から調製したEDTA抽出物、および精製された髄膜炎菌B多糖を含んだ。被嚢多糖のすべてがEDTA処理によって放出されたことを確実にするために、同じインヒビションELISAを、被嚢抽出物と同じ緩衝液および容積に再懸濁した細胞ペレットを用いて実施した。細胞ペレットからの観察可能な阻害活性は、被嚢抽出物で見られる活性の0%と10%との間であった。後の方の高い方の百分率は、最も多い量の被嚢を生成する菌株の細胞ペレットから生じた。
観察され得るように、ラットあたり2μg用量の陽性抗被嚢コントロールは、両菌株に対して防御的であった。1:5または1:25希釈の抗rNspA抗血清は、菌株8047によって引き起こされた菌血症に対して防御した。しかし、いずれの希釈度も、M986菌血症の防御において効果的でなかった。
NspAの二次構造のモデルを図32に示す。これは、8つの膜貫通β鎖および4つの表面露出連結ループを含む。これは、多くのβバレルポーリンに特徴的な、NspAの疎水性アミノ酸および親水性アミノ酸が交互するパターンにあてはまる[Weissら(1990)FEBS Letts 267:268−272]。
Claims (1)
- 本願明細書に記載された発明。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9911692.3A GB9911692D0 (en) | 1999-05-19 | 1999-05-19 | Antigenic combinations |
GB9911692.3 | 1999-05-19 | ||
GB9919705.5 | 1999-08-19 | ||
GBGB9919705.5A GB9919705D0 (en) | 1999-08-19 | 1999-08-19 | Antigenic combinations |
GB0005730A GB0005730D0 (en) | 2000-03-09 | 2000-03-09 | Antigenic combinations |
GB0005730.7 | 2000-03-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000620102A Division JP5622344B2 (ja) | 1999-05-19 | 2000-05-19 | Neisseria配合組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2013047274A true JP2013047274A (ja) | 2013-03-07 |
Family
ID=27255587
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000620102A Expired - Fee Related JP5622344B2 (ja) | 1999-05-19 | 2000-05-19 | Neisseria配合組成物 |
JP2007138403A Pending JP2007224047A (ja) | 1999-05-19 | 2007-05-24 | Neisseria配合組成物 |
JP2012256105A Pending JP2013047274A (ja) | 1999-05-19 | 2012-11-22 | Neisseria配合組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000620102A Expired - Fee Related JP5622344B2 (ja) | 1999-05-19 | 2000-05-19 | Neisseria配合組成物 |
JP2007138403A Pending JP2007224047A (ja) | 1999-05-19 | 2007-05-24 | Neisseria配合組成物 |
Country Status (14)
Country | Link |
---|---|
US (9) | US7862827B2 (ja) |
EP (6) | EP2258851A1 (ja) |
JP (3) | JP5622344B2 (ja) |
CN (2) | CN100338218C (ja) |
AU (3) | AU783894B2 (ja) |
BR (1) | BR0010721A (ja) |
CA (3) | CA2373236C (ja) |
CY (2) | CY1117235T1 (ja) |
DK (2) | DK2270173T3 (ja) |
ES (2) | ES2563650T3 (ja) |
MX (1) | MXPA01011867A (ja) |
NZ (4) | NZ536676A (ja) |
PT (2) | PT2270172E (ja) |
WO (1) | WO2000071725A2 (ja) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0935659A1 (en) | 1996-09-17 | 1999-08-18 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
PT1645631E (pt) | 1998-05-01 | 2008-02-04 | Novartis Vaccines & Diagnostic | Anitigénios da neisseria meningitidis e composições |
US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
NZ581940A (en) | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
CN100338218C (zh) | 1999-05-19 | 2007-09-19 | 启龙股份公司 | 组合式奈瑟球菌组合物 |
GB9916529D0 (en) * | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
CA2864069A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
RU2299906C2 (ru) * | 2000-02-28 | 2007-05-27 | Новартис Вэксинс Энд Диагностикс С.Р.Л. | Гетерологичная экспрессия белков neisseria |
AU2004203417B2 (en) * | 2000-05-08 | 2008-02-14 | Microscience Limited | Virulence genes, proteins, and their use |
GB0012079D0 (en) * | 2000-05-18 | 2000-07-12 | Microscience Ltd | Virulence gene and protein, and their use |
GB0020952D0 (en) * | 2000-08-24 | 2000-10-11 | Microscience Ltd | Genes and proteins and their uses |
CN100556459C (zh) | 2001-01-23 | 2009-11-04 | 安万特巴斯德公司 | 多价脑膜炎球菌多糖-蛋白质缀合疫苗 |
US7261901B2 (en) | 2001-01-31 | 2007-08-28 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
US7250172B2 (en) | 2001-01-31 | 2007-07-31 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
GB0108024D0 (en) | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
GB0114940D0 (en) * | 2001-06-19 | 2001-08-08 | Chiron Spa | Gene expression during meningococcus adhesion |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
CA2452836C (en) | 2001-07-27 | 2012-11-27 | Chiron Srl | Meningococcus adhesins nada, app and orf 40 |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
AU2012202488B2 (en) * | 2001-09-06 | 2014-01-16 | Glaxosmithkline Biologicals S.A. | Hybrid and tandem expression of Neisserial proteins |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0220197D0 (en) * | 2002-08-30 | 2002-10-09 | Univ Utrecht | Refolding method |
SI1524993T1 (sl) | 2002-08-02 | 2013-07-31 | Glaxosmithkline Biologicals S.A. | Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov |
BR0313100A (pt) * | 2002-08-02 | 2005-06-21 | Glaxosmithkline Biolog Sa | Composição imunogênica, composição imunogênica isolada, vacina, método de tratamento ou prevenção de doença bacteriana gram-negativa, uso da vacina, cepa bacteriana gram-negativa geneticamente manipulada, método para preparar a composição imunogênica, método para preparar a vacina, método de preparar uma imunoglobulina para uso na prevenção ou tratamento de infecção neisserial, preparação de imunoglobulina, preparação farmacêutica, e, uso da preparação farmacêutica |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
JP4697706B2 (ja) | 2002-10-11 | 2011-06-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン |
EP1562982B1 (en) * | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
CA2599577A1 (en) * | 2005-03-04 | 2006-09-14 | Verenium Corporation | Nucleic acids and proteins and methods for making and using them |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
WO2007072032A2 (en) * | 2005-12-23 | 2007-06-28 | Imperial Innovations Limited | Neisseria meningitidis vaccines and their use |
CU23575A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0606 |
CU23572A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0938 |
CA2656474A1 (en) * | 2006-06-29 | 2008-01-03 | Novartis Ag | Polypeptides from neisseria meningitidis |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US9579372B2 (en) * | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
GB0810742D0 (en) * | 2008-06-12 | 2008-07-16 | Univ Nottingham | Enzyme |
JP5699081B2 (ja) * | 2008-09-05 | 2015-04-08 | アイ ディー バイオメディカル コーポレーション オブ ケベック | 新規の組成物及びアジュバント |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
IT1394288B1 (it) * | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
JP5597245B2 (ja) | 2009-03-24 | 2014-10-01 | ノバルティス アーゲー | アジュバント添加した髄膜炎菌h因子結合タンパク質 |
EP2544713A1 (en) | 2010-03-10 | 2013-01-16 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
JP2013522177A (ja) * | 2010-03-11 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | グラム陰性細菌性、例えば髄膜炎菌性の感染または疾患に対する免疫原性組成物またはワクチン |
EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
CN103189387A (zh) * | 2010-07-30 | 2013-07-03 | 格里菲斯大学 | 重组脑膜炎奈瑟氏菌PorA孔蛋白 |
PL3246044T3 (pl) | 2010-08-23 | 2021-08-23 | Wyeth Llc | Stabilne preparaty antygenów rLP2086 Neisseria meningitidis |
GB201014967D0 (en) * | 2010-09-09 | 2010-10-20 | Univ Southampton | Composition |
GB201015132D0 (en) * | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
ES2728282T3 (es) | 2010-09-10 | 2019-10-23 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
EP2613805B1 (en) | 2010-09-10 | 2019-10-23 | GlaxoSmithKline Biologicals SA | Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom |
EP2635593B1 (en) * | 2010-11-05 | 2016-09-14 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Vaccines for preventing meningococcal infections |
GB201102090D0 (en) * | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
GB201120634D0 (en) * | 2011-11-30 | 2012-01-11 | Univ Sheffield | Adjuvant polypeptide |
BR112014019166A2 (pt) * | 2012-02-02 | 2017-07-04 | Novartis Ag | promotores para expressão aumentada de proteína em meningococos |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
EP3485906A1 (en) | 2012-03-09 | 2019-05-22 | Pfizer Inc | Neisseria meningitidis compositions and methods thereof |
EP2861247B1 (en) | 2012-06-14 | 2020-12-09 | GlaxoSmithKline Biologicals SA | Vaccines for serogroup x meningococcus |
GB201211154D0 (en) * | 2012-06-22 | 2012-08-08 | Univ Southampton | Composition |
US10000545B2 (en) | 2012-07-27 | 2018-06-19 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia |
WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
US9725701B2 (en) | 2013-03-15 | 2017-08-08 | Iowa Corn Promotion Board | Prokarytoic-type isocitrate dehydrogenase and its application for improving nitrogen utilization in transgenic plants |
KR20210002757A (ko) | 2013-09-08 | 2021-01-08 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
WO2016091902A1 (en) * | 2014-12-09 | 2016-06-16 | Sanofi Pasteur | Compositions comprising n. meningitidis proteins |
MX2017010705A (es) | 2015-02-19 | 2017-12-04 | Pfizer | Composiciones de neisseria meningitidis y metodos de la misma. |
CN109890413B (zh) | 2016-09-02 | 2024-04-16 | 赛诺菲巴斯德股份有限公司 | 脑膜炎奈瑟氏菌疫苗 |
IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
WO2020023717A2 (en) * | 2018-07-25 | 2020-01-30 | The Trustees Of Indiana University | Diagnostic assay for a strain of neisseria meningitidis |
CN111394410B (zh) * | 2020-03-30 | 2022-02-01 | 江南大学 | 一种高催化活性神经氨酸合酶及应用 |
US11618902B2 (en) * | 2020-03-30 | 2023-04-04 | Jiangnan University | Bacillus subtilis for producing N-acetylneuraminic acid and application thereof |
US11579093B2 (en) | 2020-04-22 | 2023-02-14 | SciLogica Corp. | Optical component |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003413A1 (en) * | 1993-07-23 | 1995-02-02 | The Rockefeller University | High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins |
WO1996029412A1 (en) * | 1995-03-17 | 1996-09-26 | Biochem Vaccines Inc. | Proteinase k resistant surface protein of neisseria meningitidis |
WO1997028273A1 (en) * | 1996-02-01 | 1997-08-07 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
JP2003500420A (ja) * | 1999-05-19 | 2003-01-07 | カイロン エセ.ピー.アー. | Neisseria配合組成物 |
JP4399112B2 (ja) * | 1998-01-14 | 2010-01-13 | カイロン ソチエタ ア レスポンサビリタ リミタータ | NeisseriaMeningitidis抗原 |
JP4472866B2 (ja) * | 1997-11-06 | 2010-06-02 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ナイセリア抗原 |
JP5102414B2 (ja) * | 1998-05-01 | 2012-12-19 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 髄膜炎菌抗原および組成物 |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4239749A (en) * | 1979-09-27 | 1980-12-16 | United States Of America | Neisseria gonorrhoeae vaccine |
EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
NL8803111A (nl) * | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Multivalent meningococcen klasse i buitenmembraaneiwit vaccin. |
EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
DE69227898T2 (de) * | 1991-03-14 | 1999-05-12 | Imclone Systems Inc | Rekombinante hybride porinepitope |
FR2692592B1 (fr) * | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
PT624376E (pt) | 1993-05-13 | 2000-07-31 | American Cyanamid Co | Preparacao e utilizacoes de proteinas de membranas externas deficitarias em los de cocos gram-negativos |
DE69506212T2 (de) | 1994-04-20 | 1999-08-05 | Us Army | Impfstoff gegen gram-negative bakterielle infektionen |
FR2720408B1 (fr) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
BR9610484A (pt) * | 1995-09-18 | 2001-09-11 | Us Army Medical Res Material C | Processo para produção de vacinas de sub-unidades de proteosoma, não covalentemente complexadas e multivalentes |
FR2739624B1 (fr) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
AU5426098A (en) | 1996-10-24 | 1998-05-15 | Emory University | Invasion associated genes from (neisseria meningitidis) serogroup |
WO1998018931A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
PL338146A1 (en) | 1997-07-17 | 2000-09-25 | North American Vaccine | Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide |
NZ502750A (en) * | 1997-08-15 | 2002-03-01 | Univ Utrecht | Vaccination against Neisseria meningitidis disease using Neisseria outer membrane protein (OMP) in particular, lactoferrin binding protein B (LbpB) |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
AT2941U1 (de) | 1998-05-06 | 1999-07-26 | Fleischhacker Gerhard | Flexible flüssigkeitssperre |
PT1741443E (pt) | 1998-05-29 | 2014-07-31 | Novartis Vaccines & Diagnostic | Combinação de vacinas para a meningite b/c |
EP1741443B1 (en) | 1998-05-29 | 2014-05-21 | Novartis Vaccines and Diagnostics, Inc. | Combination meningitidis B/C vaccines |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
EP1144998A3 (en) * | 1998-10-09 | 2002-08-07 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
US20030215469A1 (en) | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
JP4812942B2 (ja) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強 |
NZ581940A (en) * | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
CA2371032A1 (en) | 1999-04-30 | 2000-11-09 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
CA2864069A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
EP2281571A3 (en) | 2000-01-17 | 2012-04-25 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (omv) vaccine comprising n. meningitidids serogroup b outer membrane proteins |
CA2398139A1 (en) * | 2000-01-25 | 2001-08-02 | The University Of Queensland | Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha |
RU2299906C2 (ru) | 2000-02-28 | 2007-05-27 | Новартис Вэксинс Энд Диагностикс С.Р.Л. | Гетерологичная экспрессия белков neisseria |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
WO2002009643A2 (en) | 2000-07-27 | 2002-02-07 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
AU2002252638A1 (en) | 2001-04-17 | 2002-10-28 | Children's Hospital Oakland Research Institute | Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
EP1409013B1 (en) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
CA2452836C (en) * | 2001-07-27 | 2012-11-27 | Chiron Srl | Meningococcus adhesins nada, app and orf 40 |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
SI1524993T1 (sl) | 2002-08-02 | 2013-07-31 | Glaxosmithkline Biologicals S.A. | Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
JP4697706B2 (ja) | 2002-10-11 | 2011-06-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン |
EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004054611A1 (en) | 2002-12-16 | 2004-07-01 | Nasjonalt Folkehelseinstitutt | Meningococcal vaccine based on outer membrane proteins porb2 and pora |
EP1590459A2 (en) | 2003-01-15 | 2005-11-02 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression and compositions thereof |
CA3042073C (en) * | 2003-01-30 | 2022-09-13 | Novartis Vaccines And Diagnostics S.R.L. | Injectable vaccines against multiple meningococcal serogroups |
JP2006525330A (ja) | 2003-04-16 | 2006-11-09 | ワイエス・ホールディングス・コーポレーション | 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物 |
GB0315021D0 (en) | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
JP4738339B2 (ja) * | 2003-10-02 | 2011-08-03 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 複数の髄膜炎菌血清群についての液体ワクチン |
JP5173194B2 (ja) | 2003-12-23 | 2013-03-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0409748D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
CN101107007B (zh) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗 |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
WO2008001244A2 (en) | 2006-06-23 | 2008-01-03 | Harun Aksoy | A stone |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US20100150912A1 (en) | 2007-04-11 | 2010-06-17 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
ES2555786T3 (es) | 2007-06-04 | 2016-01-08 | Glaxosmithkline Biologicals Sa | Formulación de vacunas contra la meningitis |
CA2695467A1 (en) | 2007-08-02 | 2009-03-26 | Children's Hospital & Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
AU2009223613B2 (en) | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
RU2477145C2 (ru) | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
AU2009288095A1 (en) | 2008-09-03 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Peptides presenting an epitope of a domain of factor H binding protein and methods of use |
GB0816284D0 (en) | 2008-09-05 | 2008-10-15 | Nat Biolog Standards Board | Vaccine |
IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
AU2010227221B2 (en) | 2009-03-24 | 2015-01-22 | Novartis Ag | Combinations including pneumococcal serotype 14 saccharide |
JP5597245B2 (ja) | 2009-03-24 | 2014-10-01 | ノバルティス アーゲー | アジュバント添加した髄膜炎菌h因子結合タンパク質 |
EP2544713A1 (en) | 2010-03-10 | 2013-01-16 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
BR122021020829B8 (pt) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada |
US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
-
2000
- 2000-05-19 CN CNB008106002A patent/CN100338218C/zh not_active Expired - Fee Related
- 2000-05-19 CA CA2373236A patent/CA2373236C/en not_active Expired - Fee Related
- 2000-05-19 EP EP10179168A patent/EP2258851A1/en not_active Withdrawn
- 2000-05-19 BR BR0010721-2A patent/BR0010721A/pt not_active IP Right Cessation
- 2000-05-19 PT PT101782381T patent/PT2270172E/pt unknown
- 2000-05-19 EP EP10179491A patent/EP2270174A1/en not_active Withdrawn
- 2000-05-19 WO PCT/IB2000/000828 patent/WO2000071725A2/en active IP Right Grant
- 2000-05-19 NZ NZ536676A patent/NZ536676A/en not_active IP Right Cessation
- 2000-05-19 NZ NZ545647A patent/NZ545647A/en not_active IP Right Cessation
- 2000-05-19 CN CN2011104630251A patent/CN102580072A/zh active Pending
- 2000-05-19 DK DK10179061.6T patent/DK2270173T3/en active
- 2000-05-19 DK DK10178238.1T patent/DK2270172T3/en active
- 2000-05-19 MX MXPA01011867A patent/MXPA01011867A/es active IP Right Grant
- 2000-05-19 EP EP00935438A patent/EP1179072A2/en not_active Ceased
- 2000-05-19 AU AU50977/00A patent/AU783894B2/en not_active Ceased
- 2000-05-19 CA CA2929348A patent/CA2929348A1/en not_active Abandoned
- 2000-05-19 ES ES10178238.1T patent/ES2563650T3/es not_active Expired - Lifetime
- 2000-05-19 NZ NZ528254A patent/NZ528254A/en not_active IP Right Cessation
- 2000-05-19 PT PT101790616T patent/PT2270173E/pt unknown
- 2000-05-19 EP EP07075627A patent/EP1860191A3/en not_active Withdrawn
- 2000-05-19 CA CA2838395A patent/CA2838395C/en not_active Expired - Fee Related
- 2000-05-19 JP JP2000620102A patent/JP5622344B2/ja not_active Expired - Fee Related
- 2000-05-19 EP EP10179061.6A patent/EP2270173B1/en not_active Expired - Lifetime
- 2000-05-19 NZ NZ515935A patent/NZ515935A/xx not_active IP Right Cessation
- 2000-05-19 EP EP10178238.1A patent/EP2270172B1/en not_active Expired - Lifetime
- 2000-05-19 ES ES10179061.6T patent/ES2563677T3/es not_active Expired - Lifetime
-
2004
- 2004-11-05 US US10/982,703 patent/US7862827B2/en not_active Expired - Fee Related
- 2004-11-09 US US10/984,376 patent/US20050244436A1/en not_active Abandoned
-
2006
- 2006-03-20 AU AU2006201153A patent/AU2006201153B2/en not_active Ceased
-
2007
- 2007-05-24 JP JP2007138403A patent/JP2007224047A/ja active Pending
-
2009
- 2009-02-27 AU AU2009200865A patent/AU2009200865B2/en not_active Ceased
-
2010
- 2010-12-27 US US12/979,239 patent/US20110104193A1/en not_active Abandoned
-
2012
- 2012-02-03 US US13/366,226 patent/US20120135026A1/en not_active Abandoned
- 2012-11-22 JP JP2012256105A patent/JP2013047274A/ja active Pending
-
2013
- 2013-06-18 US US13/921,087 patent/US20140037668A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/284,326 patent/US20150174231A1/en not_active Abandoned
-
2016
- 2016-02-03 US US15/015,041 patent/US9364528B1/en not_active Expired - Fee Related
- 2016-02-03 US US15/015,004 patent/US9610342B2/en not_active Expired - Fee Related
- 2016-03-01 CY CY20161100173T patent/CY1117235T1/el unknown
- 2016-03-01 CY CY20161100175T patent/CY1117239T1/el unknown
-
2017
- 2017-02-21 US US15/438,584 patent/US20170165346A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003413A1 (en) * | 1993-07-23 | 1995-02-02 | The Rockefeller University | High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins |
WO1996029412A1 (en) * | 1995-03-17 | 1996-09-26 | Biochem Vaccines Inc. | Proteinase k resistant surface protein of neisseria meningitidis |
WO1997028273A1 (en) * | 1996-02-01 | 1997-08-07 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
JP4472866B2 (ja) * | 1997-11-06 | 2010-06-02 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ナイセリア抗原 |
JP4399112B2 (ja) * | 1998-01-14 | 2010-01-13 | カイロン ソチエタ ア レスポンサビリタ リミタータ | NeisseriaMeningitidis抗原 |
JP5102414B2 (ja) * | 1998-05-01 | 2012-12-19 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 髄膜炎菌抗原および組成物 |
JP2003500420A (ja) * | 1999-05-19 | 2003-01-07 | カイロン エセ.ピー.アー. | Neisseria配合組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5622344B2 (ja) | Neisseria配合組成物 | |
EP1322328B1 (en) | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis | |
US8029807B2 (en) | Outer membrane vesicles and uses thereof | |
AU2019318120B2 (en) | Modified meningococcal fHbp polypeptides | |
NZ537976A (en) | Hybrid and tandem expression of neisserial proteins | |
AU744733B2 (en) | Neisseria lactoferrin binding protein | |
EP1572729B1 (en) | Mutant frpb protein and refolding method | |
AU2016228231A1 (en) | Combination Neisserial compositions | |
US20090297547A1 (en) | Pharmaceutical composition containing the nmb0938 protein | |
RU2244749C2 (ru) | Композиция для лечения или профилактики инфекции, вызванной бактерией neisseria | |
RU2335505C2 (ru) | Белок nmb0928 и его применение в фармацевтических композициях | |
US20090208521A1 (en) | Pharmaceutical compositions containing protein nma0939 | |
US20100172931A1 (en) | Pharmaceutical Composition Containing the NMB1796 Protein | |
US20100129387A1 (en) | Pharmaceutical composition containing the nmb0606 protein | |
MXPA06006267A (en) | Protein nmb0928 and use thereof in pharmaceutical formulations | |
MX2008008580A (en) | Pharmaceutical compositions containing protein nma0939 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140415 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140418 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141127 |